Publisher: Bentham Science Publishers
E-ISSN: 1875-5828|15|5|429-442
ISSN: 1567-2050
Source: Current Alzheimer Research, Vol.15, Iss.5, 2018-03, pp. : 429-442
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Method: Using latent variable analysis, we thoroughly investigated the relationship between cognitiveimpairment, as assessed on the ADAS-Cog, and cerebral atrophy. A biomarker was developed for Alzheimer#39;sclinical trials that combines cognitive and atrophy markers. Results: Atrophy within specific brain regions was found to be closely related with impairment in cognitivedomains of memory, language, and praxis. The proposed biomarker showed significantly better sensitivityin tracking progression of cognitive impairment than the ADAS-Cog in simulated trials and areal world problem. The biomarker also improved the selection of MCI patients (78.8#177;4.9% specificityat 80% sensitivity) that will evolve to Alzheimer#39;s disease for clinical trials. Conclusion: The proposed biomarker provides a boost to the efficacy of clinical trials focused in themild cognitive impairment (MCI) stage by significantly improving the sensitivity to detect treatmenteffects and improving the selection of MCI patients that will evolve to Alzheimer’s disease.